Psilocybin, what the evidence shows.

Depression

What the strongest trials show

The 2021 New England Journal trial compared two doses of psilocybin against six weeks of escitalopram (Lexapro) in adults with moderate-to-severe depression. Both groups improved on the primary depression measure. On secondary measures, including well-being, social functioning, and emotional responsiveness, psilocybin pulled ahead.

The Johns Hopkins trial published in JAMA Psychiatry the same year focused on major depressive disorder rather than treatment resistance. Two doses of psilocybin produced rapid and substantial reductions in depression scores that held at the one-month follow-up.

What matters here is not the headline that psilocybin reduces depression. It is that two carefully supervised dosing sessions produced effects comparable to daily SSRI use, with a different mechanism and a different side-effect profile. The trials remain small. The follow-up windows are short by chronic-illness standards. The therapeutic frame around the dose is doing real work, and we still do not have a clean way to disentangle the molecule from the support.

End-of-life and existential anxiety

The cleanest evidence in the field

Some of the most striking psilocybin research has come from cancer patients facing existential distress. The 2016 Hopkins and NYU trials, run in parallel, gave single high-dose psilocybin sessions to people contending with cancer-related anxiety and depression. Both trials reported substantial, sustained relief. The four-year follow-up paper showed many of those gains persisted.

Whatever model of mind one prefers, the data are hard to argue with. People near the end of life who had carried clinical depression and anxiety for months or years described, after a single session, a coherent reorientation toward what mattered. That is not a small claim, and the evidence is not weak.

Addiction

Tobacco, alcohol, and rigid patterns

The 2014 Hopkins smoking-cessation pilot reported 80 percent abstinence at six months, against a backdrop where most evidence-based smoking interventions struggle to clear 35 percent. The sample was small and open-label, and the result has not yet been replicated at scale, but it remains one of the highest cessation rates ever reported.

The 2022 JAMA Psychiatry alcohol-use-disorder trial is more rigorous, a double-blind RCT with a placebo comparator. Participants who received psilocybin had significantly fewer heavy drinking days over the 32 weeks of follow-up. Across substances, the working theory is that psilocybin temporarily loosens the rigid cognitive patterns that hold addictive behavior in place. The therapeutic work decides whether anything sticks.

The legal landscape, in plain terms

US framework, 2026

At the federal level, psilocybin remains a Schedule I substance. That has not changed. The FDA has granted breakthrough therapy designation to several psilocybin programs, but no medicine has received final approval.

Two states have built regulated frameworks under their own authority. Oregon's Measure 109 program, operational since 2023, licenses service centers and facilitators for supervised psilocybin sessions. Colorado's Proposition 122 program, which began service rollout in 2025, takes a different shape, with a natural-medicine focus and provisions for personal use.

Outside those two state programs, supervised legal access in the United States exists only inside federally approved clinical trials. Soul Syndicate's editorial position is that the difference between a regulated session and an unregulated one is large, and that the regulatory gap is the most important structural fact about this field right now.

What we are still careful about

Where the literature is thinner than the conversation

The trials we have were run on people without a family history of psychosis, with careful screening, in clinical settings, with trained therapists, and with weeks of preparation and integration around the dose. The safety profile in that frame looks good. Outside that frame, we have surveys and self-report, not RCT-grade evidence.

Microdosing is the clearest example. The practice means taking a dose so small it produces no noticeable high, on a regular schedule, in the hope of steadier mood, sharper focus, or more creativity. It is widely practiced and widely believed in, and the science has not kept pace with the enthusiasm.

The most rigorous test so far is a 2021 study from Imperial College London, led by Balázs Szigeti. Participants ran their own placebo-controlled trial at home: each person prepared a mix of capsules, some holding a real microdose and some empty, then took them day to day without knowing which was which. People did report feeling better. But those who had unknowingly taken the empty capsules improved about as much as those who took the real dose. The benefit tracked what people expected to feel, not what they had actually taken.

That does not prove microdosing has no effect. It means the best blinded evidence we have does not support the strongest claims made for it.

And finally, the field has a marketing problem. The line between credible scientific reporting and breathless commercial promotion is thinner than it should be. We try, in everything we publish, to stay on the credible side of that line. When we are not sure, we say so.